Homepage Bottom Left
-
Héma-Québec tender selects an extended half-life FVIII
Héma-Québec announced on November 30, following its Request for Proposals for recombinant factor VIII concentrates, that it had selected Esperoct. Esperoct is approved by Health...
-
Hemophilia A gene therapy approved in Europe but possibly delayed in the U.S.
Last August, the European Medicines Agency (EMA) granted conditional marketing authorization to BioMarin’s Roctavian (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A...
-
Hemophilia B gene therapy approved by U.S. FDA
Montreal – November 28, 2022 – The U.S. Food and Drug Administration (FDA) approved the first gene therapy for hemophilia B on November 22. Etranacogene...
-
2023 CHS National Awards
Each year the CHS honours individuals who have made a significant contribution to improving the quality of life of people with bleeding disorders. The 2023...
-
Update on the issue of HIV non-disclosure
HIV Justice News published the following on October 28: “The past two weeks has seen some important HIV Justice advances in three countries – Canada,...